Uncategorized
CAR T Manufacturing Innovation Expands Patient Access
As the next generation of CAR T therapies moves closer to broader commercialization, industry leaders say the future will depend less on choosing between ex vivo and in vivo approaches and more on advancing both in parallel. Improvements in manufacturing, automation, and vector engineering are expected to expand patient access while addressing long-standing challenges around scalability, cost, and consistency.
Speaking to GEN, experts from VIVEbiotech, Terumo Blood and Cell Technologies, and Bracco describe an industry transitioning from demonstrating scientific feasibility to building robust manufacturing systems capable of delivering life-changing therapies to many more patients.
Parallel paths for CAR T innovation
“Ex vivo CAR T therapies will continue to play a critical role, while in vivo approaches are rapidly advancing and have the potential to broaden patient access by simplifying treatment pathways,” Natalia Elizalde, PhD, chief business development officer at VIVEbiotech, says.
Rather than viewing the two technologies as competitors, she expects them to develop side by side, each serving different clinical and operational needs. According to Elizalde, the industry’s priorities are shifting beyond proof-of-concept toward making therapies more widely available and economically sustainable.
She identifies advances in lentiviral vector engineering and targeted delivery technologies as major drivers of future progress. Improvements in manufacturing scalability and process robustness will also be crucial as commercial demand grows.
“The future of CAR T will not be defined by a single technological approach,” Elizalde says. “It will be defined by the ability of different platforms to address unmet patient needs while improving scalability, accessibility, and sustainability.”
Automation tackles manufacturing variability
While scientific innovation continues, manufacturing remains one of the biggest barriers to broader adoption. According to Wenyan Leong, PhD, director, APAC commercial, cell and gene therapies at Terumo Blood and Cell Technologies, the greatest challenge in ex vivo CAR T production is not any individual manufacturing step but the cumulative variability created throughout the workflow.
“Every manual intervention, open manipulation, operator-dependent activity, and process handoff introduces opportunities for variability, deviation, and operational complexity,” Leong says.
That variability extends from cell collection through processing, expansion, quality control, and final-product release. As manufacturers scale production, maintaining consistent product quality becomes increasingly difficult and expensive.
Leong believes automation offers a practical solution, although implementation should be tailored to each developer’s manufacturing strategy rather than applied universally.
“A useful framework is to automate where risk is highest, where variability has the greatest impact on product quality, and where scaling creates the most operational burden,” she explains.
For many manufacturers, cell expansion represents the most logical place to automate because it is labor-intensive, highly dependent on operator expertise, and difficult to reproduce consistently across multiple sites. By reducing manual processes and simplifying operations, manufacturers can lower costs while improving reproducibility and expanding patient access, Leong says.
Integrated manufacturing supports industrialization
Sophie He, PhD, vice president, cell therapy at Bracco, points to additional manufacturing bottlenecks that continue to slow commercialization. For example, she says ex vivo CAR T manufacturing must overcome complex supply chains, logistical challenges, and significant analytical demands that increase both timelines and production costs.
“In autologous manufacturing, patient-to-patient variability and poor starting-cell quality lead to inconsistent transfection and expansion,” He says. “In allogeneic approaches, the priority is obtaining highly pure starting material before stem cell differentiation into T cells.”
He also highlights fragmented cell selection and activation workflows as major contributors to cellular stress, inconsistent yields, and reduced product quality across both therapy modalities.
“Integrating multiple processing steps, such as cell selection and activation, into a single closed, continuous workflow reduces handling, washing, production time, and cost while improving cell viability and consistency,” He says.
According to He, combining workflow integration with automation and flexible manufacturing models, including point-of-care production, will enable reliable, high-throughput, and cost-effective CAR T manufacturing.
Taken together, these experts see the future of CAR T therapies resting on a combination of scientific advances and manufacturing innovation. As vector technologies mature and automated production becomes more sophisticated, both ex vivo and in vivo approaches are expected to complement one another, creating a more scalable and accessible ecosystem capable of bringing advanced cell therapies to far more patients.
The post CAR T Manufacturing Innovation Expands Patient Access appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read